Maintenance therapy for metastatic nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether taking two oral drugs (capecitabine and toripalimab) after your first treatment can keep your nasopharyngeal cancer from growing. It is for people whose cancer has spread and responded well to initial therapy, and aims to see if this maintenance approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer that has spread to other parts of the body.
- You are between 18 and 65 years old.
- You finished your first round of chemotherapy (gemcitabine/cisplatin) plus immunotherapy (toripalimab) and your tumor shrank a lot or disappeared.
- You are in good enough health to care for yourself and do light activities (ECOG 0 or 1).
- Your blood counts and liver and kidney function are within normal limits.
- You do not have serious health conditions like active infections, autoimmune disease, or major heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug toripalimab to the chemotherapy pill capecitabine after standard treatment helps prevent nasopharyngeal cancer from coming back. It is for people with high-risk features who have already had chemo and radiation.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
This trial tests a combination of two drugs—tislelizumab (an immunotherapy that helps your immune system fight cancer) and capecitabine (a chemo pill taken daily)—as maintenance therapy after initial chemotherapy for high-risk nasopharyngeal cancer. The goal is to see if this approach can lower the chance of cancer coming back.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can help people whose nasopharyngeal cancer has come back or spread. It is for those who haven't yet received other treatments for this advanced stage.
This trial is testing whether adding a new form of chemotherapy (mitoxantrone hydrochloride liposome injection) to capecitabine (a standard chemotherapy pill) helps people with advanced nasopharyngeal carcinoma live longer or control their cancer better than capecitabine alone. You may be eligible if your cancer has progressed after platinum-based chemotherapy.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
Hear when a new Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.